Key Performance
More- Earnings Score: N/A
- Momentum Score: 22
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Rosen Law Firm reminds investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) who purchased securities between November 26, 2025 and August 28, 2026 of the November 30, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to former CEO Christopher Missling's misconduct, and misrepresented the company's business and prospects.
11/09/2026, 6:46 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp., Honeywell Aerospace Inc., and Gildan Activewear Inc., alleging false and misleading statements. The firm is seeking lead plaintiffs with a November 30, 2026 deadline. Investors who purchased securities during specified class periods may be eligible for compensation.
11/06/2026, 9:33 PM • GlobeNewswire
A class action lawsuit has been filed against Anavex Life Sciences Corp. for alleged securities violations between November 26, 2025 and August 28, 2026. The complaint alleges the company and its executives made false statements regarding adequate internal controls, understated regulatory challenges related to former CEO Christopher Missling's misconduct, and misrepresented business operations and prospects. Investors who suffered losses can apply to be lead plaintiff by November 30, 2026.
11/03/2026, 5:57 PM • GlobeNewswire
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, transitioning from her interim role. Under her leadership, the company has achieved key milestones including FDA clearance of its IND application for blarcamesine in Fragile X syndrome, completion of clinical pharmacology studies, and progress on its Phase 3 Rett syndrome program. Kellmeyer brings over 30 years of biopharmaceutical industry experience in clinical development and regulatory affairs.
11/03/2026, 7:00 AM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against six companies: Tigo Energy (TYGO), Fluence Energy (FLNC), Anavex Life Sciences (AVXL), The Ensign Group (ENSG), Netcapital Inc. (NCPL), and Webull Corporation (BULL). The lawsuits allege various forms of securities fraud including false statements, undisclosed material facts, and inadequate internal controls across the companies during specified periods in 2025-2026.
11/02/2026, 7:00 AM • GlobeNewswire
Rosen Law Firm is notifying investors about multiple securities class action lawsuits. Honeywell Aerospace faces allegations of false statements regarding supplier dependencies and cybersecurity compliance issues. Anavex Life Sciences and Ardelyx, Inc. also have pending class actions with November 2026 deadlines for lead plaintiff claims.
10/31/2026, 8:28 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and Alphabet Inc. of upcoming lead plaintiff deadlines in securities class action lawsuits. The Anavex case alleges false statements regarding internal controls and regulatory challenges related to former CEO misconduct. Investors with losses exceeding $100K are encouraged to secure counsel before the November 30, 2026 deadline.
10/31/2026, 1:22 PM • GlobeNewswire
Law firm Kirby McInerney LLP is alerting investors about pending securities fraud class action lawsuits against Alphabet Inc., Endava plc, and Anavex Life Sciences Corp. The Alphabet lawsuit involves allegations that the company failed to disclose disappointing training results for Gemini 3.5 Pro and its significant launch delay, which led to a 4.4% stock price decline on July 16, 2026. Lead plaintiff deadlines range from November 30 to December 1, 2026.
10/29/2026, 6:00 PM • GlobeNewswire
Kirby McInerney LLP announced pending federal securities class action lawsuits against Anavex Life Sciences, Endava plc, and Alphabet Inc. The Anavex lawsuit covers investors who purchased securities between November 26, 2025 and August 28, 2026, alleging false statements regarding inadequate internal controls and understated regulatory challenges following the termination of former CEO Christopher Missling. The lead plaintiff deadline is November 30, 2026.
10/29/2026, 6:00 PM • GlobeNewswire
The Law Offices of Frank R. Cruz reminds investors of lead plaintiff deadlines (November 30, 2026) in securities fraud class actions against four companies. Fluence Energy faces allegations of overstating backlog delivery capabilities, Qfin Holdings allegedly misrepresented business resilience amid regulatory challenges, Endava plc is accused of accounting treatment issues and internal control weaknesses, and Anavex Life Sciences allegedly lacked adequate internal controls and understated regulatory risks.
10/29/2026, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against Anavex Life Sciences Corp. (NASDAQ: AVXL) for allegedly making false and misleading statements regarding inadequate internal controls and understated regulatory challenges related to misconduct by former CEO Christopher Missling. Investors who purchased securities between November 26, 2025 and August 28, 2026 can apply to be lead plaintiff by November 30, 2026.
10/28/2026, 6:43 PM • GlobeNewswire
Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Anavex Life Sciences Corp. (AVXL) on behalf of investors who purchased securities between November 26, 2025 and August 28, 2026. The lawsuit alleges that Anavex made false and misleading statements regarding inadequate internal controls, understated regulatory challenges related to misconduct by former CEO Christopher Missling, and misrepresented the company's business and prospects. The lead plaintiff deadline is November 30, 2026.
10/21/2026, 6:56 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Anavex Life Sciences Corp. (AVXL) for allegedly making false statements about internal controls and regulatory challenges related to former CEO misconduct. Similar lawsuits have been filed against AppLovin Corporation (APP) and Unicycive Therapeutics, Inc. (UNCY). Investors have until November 30, 2026 to become lead plaintiffs.
10/18/2026, 3:04 PM • GlobeNewswire
Robbins LLP announced a class action lawsuit against Anavex Life Sciences Corp. for allegedly misleading investors about inadequate internal controls and regulatory challenges related to former CEO Christopher Missling's misconduct. The lawsuit covers investors who purchased AVXL securities between November 26, 2025 and August 28, 2026. The lead plaintiff deadline is November 30, 2026.
10/13/2026, 6:51 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Anavex Life Sciences, Ardelyx, and AST SpaceMobile to join securities class action lawsuits before upcoming deadlines. The lawsuits allege that these companies made false or misleading statements regarding their business operations, internal controls, and regulatory challenges. Investors who purchased securities during specified class periods may be entitled to compensation.
10/11/2026, 12:39 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 11/10/2026
Company Profile
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, as well as exhibits anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71 that targets SIGMAR1 and M1 muscarinic receptors, which is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, such as cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.